Best Grants for Biotech Startups in 2026
The best biotech grant programs in 2026 center on NIH SBIR/STTR — which is by orders of magnitude the largest single non-dilutive funder for life sciences in the world, with multiple solicitations annually across dozens of institutes. BARDA funds pandemic preparedness and biodefense. CDMRP (DoD medical research) funds specific disease-state research with congressional earmarks. NSF supports biotech with biological foundations. State programs add substantial capital in selected states: Massachusetts Life Sciences Center (with unique small business matching grants that stack on SBIR), Texas CPRIT (cancer-focused), California CIRM (regenerative medicine), and New York Empire State Development life sciences programs. Private programs from disease-specific foundations (ALS Association, Cystic Fibrosis Foundation, American Cancer Society, JDRF, and dozens of others) fund indication-specific research. Y Combinator Bio, IndieBio, and The Engine provide accelerator-grant hybrid pathways. For bootstrapped biotech founders, stacking NIH SBIR Phase I/II with state matching grants (where available) plus disease-specific foundation funding can realistically build $2M-$5M in non-dilutive capital over 24-36 months before any equity raise.
Browse the top biotech grant opportunities below, updated weekly from our database of 1,900+ listings. Filter by sub-sector (therapeutics, diagnostics, devices) and stage for best fits.
Featured Opportunities
Impact of Initial Influenza Exposure on Immunity in Infants (U01 Clinical Trial Not Allowed)
U.S. Ambassadors Fund for Cultural Preservation Freedom 250
Natural Gas Distribution Infrastructure Safety and Modernization (NGDISM) Grant Program
TX: Life Sciences & Biotechnology
Grants to Military-Connected Local Educational Agencies for the World Language Advancement and Readiness Program
FY 2026 U.S. Leadership in Education, Advanced Manufacturing, and Digital Skills (U.S. LEADS) Program
TX: Why Texas?
Prevention, Control, and Mitigation of Harmful Algal Blooms Program
TX: Texas Economic Development & Tourism Office
Renewable Resource Extension Act National Focus Fund Projects
Frequently Asked Questions
Why is NIH SBIR so important for biotech?
NIH operates one of the largest SBIR programs in the federal government with $1+ billion in annual awards. Its structure (Phase I Concept at $150K-$300K, Phase II Prototype at $1M-$2M, Phase IIB and Direct to Phase II at higher levels) is optimally suited to biotech development timelines. Multiple institutes (NCI, NIMH, NHLBI, NIA, NIAID, etc.) have distinct RFAs. Biotech founders routinely build companies on NIH SBIR as the primary capital source for years.
What's the MLSC matching grant?
The Massachusetts Life Sciences Center Small Business Matching Grant provides matching funds to MA-based life sciences companies that win federal SBIR/STTR Phase I or Phase II awards. This effectively doubles non-dilutive funding for qualifying MA companies. It's one of the country's most distinctive state-level biotech advantages and a meaningful factor in biotech location decisions.
How do disease-specific foundations fund biotech?
Disease-focused foundations (ALS Association, JDRF, Cystic Fibrosis Foundation, American Cancer Society, Susan G. Komen, Alzheimer's Association, etc.) run grant and venture philanthropy programs targeting specific indications. Structures range from pure grants to milestone-based funding to non-dilutive preferred-investor arrangements. For founders working in a specific indication, these foundations often provide more targeted capital than generic biotech programs.